One million people are struck annually from colorectal cancer
worldwide [1] and 150,000 of these come from the United States
[2]. Although hereditary nonpolyposis colorectal cancer (HNPCC),
also called Lynch syndrome [3], accounts for only 2-4% of all
colorectal cancer cases [4,5], the high incidence of colorectal
cancer, being the third most common malignancy, has stimulated
research about HNPCC. The different prevention strategy and
the role of early detection and treatment of sporadic and hereditary
colorectal cancer underline the importance of identification
of mutation carriers of HNPCC, either in healthy individuals
or in patients [6].